Immune Pharmaceuticals Inc
OTC:IMNPQ
Immune Pharmaceuticals Inc
Interest Income Expense
Immune Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Immune Pharmaceuticals Inc
OTC:IMNPQ
|
Interest Income Expense
-$3.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-181%
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Immune Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
-3.5m
USD
Based on the financial report for Dec 31, 2017, Immune Pharmaceuticals Inc's Interest Income Expense amounts to -3.5m USD.
What is Immune Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-181%
Over the last year, the Interest Income Expense growth was 66%. The average annual Interest Income Expense growth rates for Immune Pharmaceuticals Inc have been 4% over the past three years , -181% over the past five years .